| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone propionate/formoterol fumarate (Flutiform®) |
| Formulation | 50 micrograms/5 micrograms suspension for inhalation |
| Reference number | 1276 |
| Indication | Regular treatment of asthma where the use of a combination product (an inhaled corticosteroid [ICS] and a long-acting β2 agonist [LABA]) is appropriate: for patients not adequately controlled on an ICS and ‘as required’ inhaled short-acting β2 agonist, or for patients already adequately controlled on both an ICS and a LABA. Flutiform 50/5 microgram and 125/5 microgram per actuation is indicated in adults and adolescents aged 12 years and above. Flutiform 250/10 micrograms per actuation is indicated in adults only |
| Company | Napp Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 05/08/2011 |